CGEN

#3075
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
2.63
2.63
Intervallo Annuale
1.32
3.24
Variazione giornaliera
-5.40%
Variazione Mensile
+0.38%
Variazione di 6 mesi
+67.52%
Variazione Annuale
+69.68%
Chiusura Precedente
2.7 8
Open
2.6 3
Minimo
2.6 3
High
2.6 3
Volume
11
Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
4.03
Rapporto prezzo/fatturato
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

Notizie